Abstract
This editorial comments on the manuscript of Extra and colleagues in this issue of The Oncologist reporting on the use of trastuzumab for metastatic breast cancer patients.
Publication types
-
Comment
-
Editorial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Disease Progression
-
Endpoint Determination
-
Humans
-
Neoplasms / enzymology
-
Neoplasms / pathology*
-
Neoplasms / therapy*
-
Receptor, ErbB-2 / antagonists & inhibitors